Max O Meneveau
Overview
Explore the profile of Max O Meneveau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lattimore C, Meneveau M, Desai R, Camacho T, Squeo G, Showalter S
J Surg Res
. 2024 Apr;
298:277-290.
PMID: 38636184
Introduction: Despite national guidelines against contralateral prophylactic mastectomy (CPM) in low- to moderate-risk breast cancer, CPM use continues to rise. Breast reconstruction improves health-related quality of life and satisfaction among...
3.
Jones J, Agarwal A, Moorman A, Hofmeister M, Hulse J, Meneveau M, et al.
Transplant Direct
. 2023 Jul;
9(8):e1506.
PMID: 37456591
Methods: In 2018, 2 kidneys and a liver were procured from a deceased donor resident of Kentucky, one of many states that was experiencing an HAV outbreak associated with person-to-person...
4.
Meneveau M, Crawford M, Turkheimer L, Millard T, Atkins K, Showalter S
Ann Surg Oncol
. 2023 Jul;
30(10):6034-6040.
PMID: 37454014
Background: The Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER, NCT04272801) trial aims to determine whether 3 months of preoperative endocrine therapy (pre-ET) informs adjuvant radiation therapy...
5.
Tran C, Lynch K, Meneveau M, Katyal P, Olson W, Slingluff Jr C
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36746511
Background: Immune-mediated melanoma regression relies on melanoma-reactive T cells infiltrating tumor. Cancer vaccines increase circulating melanoma-reactive T cells, but little is known about vaccine-induced circulating lymphocytes (viCLs) homing to tumor...
6.
Meneveau M, Vavolizza R, Mohammad A, Kumar P, Manderfield J, Callahan C, et al.
Ann Surg
. 2022 Dec;
278(3):e589-e597.
PMID: 36538614
Objective: Develop a predictive model to identify patients with 1 pathologic lymph node (pLN) versus >1 pLN using machine learning applied to gene expression profiles and clinical data as input...
7.
Squeo G, Meneveau M, Varhegyi N, Lattimore C, Janowski E, Showalter T, et al.
J Surg Res
. 2022 Nov;
283:514-522.
PMID: 36436288
Introduction: Precision breast intraoperative radiation therapy (PB-IORT) incorporates computed tomography-guided treatment planning and high dose rate brachytherapy to deliver a single dose of highly conformal radiational therapy. The purpose of...
8.
Vavolizza R, Rabinovich E, Meneveau M, Showalter S
Surg Clin North Am
. 2022 Nov;
103(1):17-33.
PMID: 36410349
Randomized clinical trials have been essential in guiding the surgical and systemic treatment of breast cancer, with most focusing on de-escalation. Here, we discuss key clinical trials that have shaped...
9.
Lynch K, Hu Y, Farrow N, Song Y, Meneveau M, Kwak M, et al.
J Surg Oncol
. 2022 Sep;
127(1):140-147.
PMID: 36115028
Introduction: Completion lymph node dissection (CLND) for microscopic lymph node metastases has been replaced by observation; however, CLND is standard for clinically detectable nodal metastases (cLN). CLND has high morbidity,...
10.
Lattimore C, Meneveau M, Marsh K, Shada A, Slingluff Jr C, Dengel L
J Surg Res
. 2022 Jun;
278:356-363.
PMID: 35671681
Introduction: Inguinal complete lymph node dissection (CLND) for metastatic melanoma exposes the femoral vein and artery. To protect femoral vessels while preserving the sartorius muscle, we developed a novel sartorius...